Introduction
============

Coronary artery disease (CAD), one of the leading causes of death and disability worldwide, has been a significant health problem and global burden.[@b1-tcrm-14-1855] According to data from the United States, an estimated 15.4 million Americans over the age of 20 had developed CAD from 2007 to 2010, with the reported prevalence increasing with age for both genders.[@b1-tcrm-14-1855] Another study also reported an estimated 17.5 million deaths in 2005 due to CAD alone, a number that is expected to increase by 137% in males and 120% in females by 2020 in developing countries.[@b2-tcrm-14-1855] Patients with CAD usually remain asymptomatic until their first clinically significant manifestation of pathogenic conditions, such as myocardial infarction (MI), cardiac arrest, stroke, or death from cardiovascular (CV) events.

Leptin, a 16-kDa obese gene product primarily secreted by white adipocytes, is the most prominent appetite- and energy-regulating peptide discovered in the early 1990s.[@b3-tcrm-14-1855] Hyperleptinemia has been implicated in inflammatory, metabolic, and homeostatic factors involved in obesity, hypertension, and cardiovascular disease (CVD).[@b4-tcrm-14-1855],[@b5-tcrm-14-1855] Studies have revealed that leptin and its receptor's isoforms are expressed in cardiomyocytes, vascular smooth muscle cells, and endothelia.[@b6-tcrm-14-1855]--[@b9-tcrm-14-1855] Moreover, leptin resistance with hyperleptinemia has been involved in enhancing endothelial oxidative stress, stimulating the proliferation of vascular smooth muscle cells, inducing neointimal and medial thickening of injured arterial vascular walls, stimulating the formation of reactive oxygen species, and activating the renin--angiotensin--aldosterone system, which together result in the imbalance between vasoconstriction and vasodilatation with the consequent development of CVD.[@b5-tcrm-14-1855],[@b9-tcrm-14-1855]

Although the link between adipokines and CAD has been well documented, the association between serum leptin and long-term CV outcomes in patients with CAD has been rarely reported.[@b4-tcrm-14-1855],[@b10-tcrm-14-1855] Moreover, conflicting data are available concerning the association of leptin with future development of CVD.[@b11-tcrm-14-1855]--[@b13-tcrm-14-1855] In LIPID study, plasma leptin was a significant and independent predictor of recurrent CVD in men with earlier acute coronary syndromes.[@b11-tcrm-14-1855] Another study also noted high plasma leptin levels predict the congestive heart failure or cardiac death and acute coronary syndrome or stroke in patients with CAD that were followed up for two years.[@b12-tcrm-14-1855] However, serum leptin level is not associated with risk of CVD but is associated with risk of diabetes in elderly.[@b13-tcrm-14-1855] Therefore, the current study aims to determine the relationship between serum leptin levels and cardiometabolic risk factors among patients with CAD.

Patients and methods
====================

Patients
--------

Patients with \>50% stenosis in any segment after coronary angiography were identified as having CAD. After reviewing the patients' medical records between January and December 2012, 112 participants with CAD in a medical center in Hualien, eastern Taiwan were enrolled; 14 participants were excluded because of acute infection (n = 3), malignancy (n = 3), coronary bypass graft surgery (n = 2), and refusal to provide informed consent (n = 6). Finally, a total of 98 participants with CAD had been enrolled in this cross-sectional study. Using standard mercury sphygmomanometers with appropriate cuff sizes, morning BP levels of all participants who had rested for at least 10 minutes were measured on the right arm by trained staff. Systolic blood pressure (SBP) and Diastolic blood pressure (DBP) were measured three times at 5-minute intervals and were averaged for analysis. Hypertension was defined as SBP ≥140 mmHg and/or DBP ≥90 mmHg or having received any anti-hypertensive drugs in the past two weeks according to the Eighth Joint National Committee guideline. Patients having fasting plasma glucose levels ≥126 mg/dL or those using oral hypoglycemic medications or insulin were diagnosed with diabetes mellitus (DM).[@b14-tcrm-14-1855] This study had been approved by the Protection of the Human Subjects Institutional Review Board of Tzu Chi University and Hospital. All participants gave written informed consent prior to study participation.

Anthropometric analysis
-----------------------

Body weight and height were measured to the nearest 0.5 kg and 0.5 cm, respectively, with participants in light clothing without shoes. Body mass index was calculated using Quetelet's formula: weight in kilograms divided by the height in meters squared.[@b5-tcrm-14-1855],[@b15-tcrm-14-1855]--[@b17-tcrm-14-1855]

Biochemical investigations
--------------------------

After an eight-hour overnight fast, blood samples (approximately 5 mL) collected from all participants were immediately centrifuged at 3,000 *g* for 10 minutes. Serum levels of blood urea nitrogen, creatinine, fasting glucose, total cholesterol (TCH), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and C-reactive protein (CRP) were determined using an autoanalyzer (COBAS Integra 800; Hoffmann-La Roche Ltd., Basel, Switzerland).[@b5-tcrm-14-1855],[@b15-tcrm-14-1855]--[@b17-tcrm-14-1855] Serum leptin concentrations were determined using a commercially available enzyme immunoassay (SPI Bio Inc., Sherbrooke, QC, Canada).[@b5-tcrm-14-1855],[@b15-tcrm-14-1855] The estimated glomerular filtration rate was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation.[@b16-tcrm-14-1855],[@b17-tcrm-14-1855]

CV event monitoring
-------------------

The primary endpoint was the incidence of major adverse cardiovascular events (MACEs), including death from CV causes, cardiac arrest, MI, stroke, nonfatal stroke or other arterial thrombotic events, and hospitalization due to CV conditions such as unstable or progressive angina and heart failure. The follow-up time interval (months) had not been estimated until the last hospital outpatient or inpatient record had been reviewed or the last telephone interview had been conducted (June 30, 2017). Moreover, the event time (months) had not been counted until the first MACE had occurred. Patient follow-up had been performed by a study nurse who was unaware of the participants' baseline measurements and the study protocol.

Statistical analysis
--------------------

All statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS) version 19.0 (IBM Corporation, Armonk, NY, USA). The distribution pattern of the variables was determined using the Kolmogorov--Smirnov test. Normally distributed variables were expressed as mean ± standard deviation and with differences between patients being compared using the Student's independent *t*-test (two-tailed). Data not normally distributed were expressed as medians and interquartile ranges with differences between patients being compared using the Mann--Whitney *U* test (TG, fasting glucose, creatinine, CRP, and leptin). Data regarding the number of patients were analyzed using the chi-squared test. Kaplan--Meier survival curves with a log-rank test were used to estimate event-free survival during follow-up based on median leptin concentrations. Univariate and multivariate Cox regression models were used to examine factors associated with CV events. All covariates were included in the multivariate Cox regression model. A *P*-value \<0.05 was considered statistically significant.

Results
=======

Demographic, clinical, and biochemical characteristics of the 98 patients with CAD are shown in [Table 1](#t1-tcrm-14-1855){ref-type="table"}. A total of 47 (48.0%) and 76 (77.6%) patients had DM and hypertension, respectively. The high leptin group (median leptin concentration \>6.03 ng/mL) was older (*P* = 0.024), had higher serum levels of CRP (*P* = 0.015) and leptin (*P*\<0.001), and was shorter in height (*P* = 0.027) than the low leptin group (median leptin concentration ≤6.03 ng/mL). Drugs used by the patients included angiotensin-converting enzyme inhibitors (ACEi; n = 29; 29.6%), angiotensin receptor blockers (ARB; n = 37; 37.8%), β-blockers (n = 58; 59.2%), calcium channel blockers (CCB; n = 33; 33.7%), statins (n = 71; 72.4%), and fibrate (n = 14; 14.3%). No statistically significant difference in sex, comorbidity with DM or hypertension, and use of ACEi, ARB, β-blockers, CCB, statins, or fibrate had been found between the two leptin groups.

After a median follow-up of 52 months, 43 CV events had occurred. Patients with CV events had higher SBP (*P* = 0.030), serum TCH (*P* = 0.034), CRP (*P* = 0.018), and leptin (*P* = 0.001) levels than those without CV events. No statistically significant differences in sex, comorbidity with DM or hypertension, and use of ACEi, ARB, β-blockers, CCB, statins, or fibrate had been observed between those with and without CV events ([Table 2](#t2-tcrm-14-1855){ref-type="table"}).

Kaplan--Meier analysis showed that the cumulative incidence of CV events was greater in the high leptin group (median leptin concentration \>6.03 ng/mL) than in the low leptin group (log-rank *P* = 0.012) ([Figure 1](#f1-tcrm-14-1855){ref-type="fig"}). Univariate Cox regression analysis revealed that SBP (HR: 1.018; 95% CI: 1.003--1.034; *P* = 0.021), TCH (HR: 1.010; 95% CI: 1.001--1.020; *P* = 0.035), TG (HR: 1.004; 95% CI: 1.001--1.006; *P* = 0.006), CRP (HR: 4.329; 95% CI: 2.027--9.246; *P* \< 0.001), and leptin (HR: 1.043; 95% CI: 1.025--1.062; *P* \< 0.001) levels were positively associated with CV events in patients with CAD. Furthermore, multivariate Cox regression analysis showed that TG (HR: 1.010; 95% CI: 1.001--1.018; *P* = 0.022) and leptin (HR: 1.054; 95% CI: 1.026--1.082; *P* \< 0.001) levels were independently associated with CV events in patients with CAD ([Table 3](#t3-tcrm-14-1855){ref-type="table"}).

Discussion
==========

The results presented herein revealed that patients with CAD who developed MACEs during follow-up had higher fasting leptin levels than those who did not. Moreover, fasting serum leptin and TG levels were independently associated with increased risk for MACEs among patients with CAD.

Aging is usually associated with hyperleptinemia and leptin resistance, which may aggravate age-associated pathologies, including metabolic syndrome and CVD.[@b18-tcrm-14-1855],[@b19-tcrm-14-1855] The present study also revealed that patients in the high leptin group were older than those in low leptin group. Hypertension has been a major independent risk factor for CAD across all age, gender, and race groups.[@b20-tcrm-14-1855] A previous large-scale meta-analysis involving approximately 1 million adults had revealed that BP was correlated with fatal CAD across all ages and that an overall SBP increase of 20 mmHg doubles the risk for fatal coronary events.[@b21-tcrm-14-1855] A recent systematic review and meta-analysis had also confirmed that intensive BP reductions had additional benefits on major CV events and all-cause mortality.[@b22-tcrm-14-1855] Accordingly, the present study also revealed that patients with CAD who developed a new MACE had significantly higher SBP than those who did not, suggesting that BP reduction is important for preventing further MACE development in patients with CVD. Several previous studies have suggested that inflammation and dyslipidemia may play important roles in not only the occurrence and progression of coronary atherosclerotic lesions but also treatment outcome after intervention.[@b23-tcrm-14-1855]--[@b25-tcrm-14-1855] The present study also observed significantly higher CRP values in the high serum leptin group than in low leptin group. Moreover, significantly higher TCH and CRP levels were found in those who developed a new MACE than in those who did not, which is consistent with a previous study by Xu et al.[@b25-tcrm-14-1855]

In contrast with traditional risk factors for CAD, growing evidence has revealed that leptin resistance with hyperleptinemia, a phenomenon encountered in obesity and insulin resistance, plays an important role in the occurrence, severity, and extent of CV events.[@b10-tcrm-14-1855],[@b15-tcrm-14-1855],[@b26-tcrm-14-1855],[@b27-tcrm-14-1855] Although the definitive role of leptin in the development of CVD remains to be clarified. One study noted lower serum leptin level that measured 7 days after acute MI onset is associated with a high incidence of adverse events in Japanese patients.[@b28-tcrm-14-1855] Another study noted low serum leptin level is independent predictors of high risk coronary anatomy as defined by an integrated coronary computed tomography angiography risk score in patients with stable chest pain.[@b29-tcrm-14-1855] Our previous study and several other reports had found that high circulating leptin levels were positively correlated with the number of stenotic coronary arteries.[@b15-tcrm-14-1855],[@b26-tcrm-14-1855] Hyperleptinemia was associated with heart failure and impaired diastolic function in patients with CAD.[@b30-tcrm-14-1855] In addition, leptin exhibited profibrotic effects on the myocardium, which could induce myocardial fibrosis and aggravate the severity of heart disease.[@b31-tcrm-14-1855] Leptin is also an independent predictor of CV event recurrence in males with earlier acute coronary syndromes, while hyperleptinemia has been positively associated with restenosis rate after percutaneous coronary intervention.[@b11-tcrm-14-1855] Moreover, after both univariate and multivariate Cox regression analyses, a very recent study revealed that circulating leptin levels could significantly predict the occurrence of not only MACEs, such as short-term congestive heart failure events, cardiac deaths, or acute coronary syndromes, but also strokes.[@b12-tcrm-14-1855] Our present findings also revealed that patients with CAD who developed a new MACE had significantly higher serum leptin levels than those who did not. Taken together, whether the complex interaction of leptin with metabolic and CV system could account for a "CAD progression" effect needs further study.

The present study showed that hyperleptinemia and hypertriglyceridemia independently and significantly increased the risk of MACE in patients with CAD after univariate and multivariate Cox regression analyses. The mechanism by which leptin induces adverse CV events among patients with CAD is likely to be multifactorial. Leptin had also been identified as an adipokine that could potentially be involved in crosstalk between adipose tissues and the vascular wall.[@b7-tcrm-14-1855],[@b8-tcrm-14-1855],[@b31-tcrm-14-1855] Hyperleptinemia had been associated with intima--media thickness of the common carotid artery, smooth muscle cell migration and proliferation, and coronary artery calcification, all of which were markers of asymptomatic atherosclerosis and important pathological vascular changes in patients with hypertension and CAD.[@b7-tcrm-14-1855],[@b31-tcrm-14-1855]--[@b33-tcrm-14-1855] The direct influence of hypertension on future CV events has been well documented. A previous study also reported that hyperleptinemia was positively associated with hypertension.[@b34-tcrm-14-1855] Based on findings from Cox regression analyses, the present study confirmed that elevated SBP increased the risk of MACEs among patients with CAD, suggesting that hyperleptinemia may aggravate hypertension-induced MACEs.

CRP, a well-established biomarker of inflammation, has been positively associated with CAD presence and progression.[@b24-tcrm-14-1855] Previous studies had revealed that high leptin and CRP levels increase the risk for CV death in Western countries and Taiwan.[@b35-tcrm-14-1855],[@b36-tcrm-14-1855] Leptin has been associated with a pro-inflammatory, atherogenic milieu, while several studies had reported that serum leptin levels were positively correlated with hs-CRP levels.[@b37-tcrm-14-1855],[@b38-tcrm-14-1855] Our previous study also revealed that elevated CRP levels were independent predictors of hyperleptinemia among patients with hypertension.[@b5-tcrm-14-1855] Accordingly, the current study revealed that among patients with CAD, those who developed a new MACE had significantly higher CRP levels than those who did not. Associations between leptin and pro-atherogenic blood lipids, along with leptin's pro-inflammatory activity and role in insulin resistance and endothelial dysfunction, comprise the major mechanisms for triggering atherosclerosis and further aggravating CVD.[@b10-tcrm-14-1855]

Limitations
-----------

Some limitations to the present study are worth mentioning. First, the limited number of patients with MACE, uneven distribution of sex, not included obesity subjects, obtained from a single center, as well as the lack of evaluation regarding some lifestyle habits that could influence the occurrence of MACE, such as smoking or alcohol drinking, may restrict the predictive power of the current study. Second, although several of the medications used by our study population may influence their atherosclerotic and inflammatory status, the present study showed that ACEi, ARB, β-blockers, CCB, statins, and fibrates had no influence on circulating leptin levels or new MACE development. Many independent studies have reported that the pleiotropic effects of statins included modulation of serum leptin levels, while treatment with atorvastatin lowered circulating leptin levels in patients with CAD.[@b39-tcrm-14-1855],[@b40-tcrm-14-1855] A previous study also revealed that lipid profiles, including TG, TCH, LDL-C, and HDL-C, have poor predictive values for the severity of coronary diseases due to the influence of drug therapy.[@b41-tcrm-14-1855] Further studies are needed to evaluate the impact of the aforementioned medication on serum leptin concentrations and new MACE development among patients with CAD.

Conclusion
----------

In addition to the traditional risk factors for CAD, hyperleptinemia may serve as a novel, independent risk factor for CV events among patients with CAD and may increase the predictive power for MACEs. Moreover, while a previous study revealed that circulating leptin levels could serve as an additional tool for short-term risk stratification of patients with CAD,[@b26-tcrm-14-1855] our results showed that such a finding could be further extended to include long-term CV events among patients with CAD. Further studies are needed to evaluate the direct cause-and-effect association between serum leptin and CAD can be established.
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###### 

Clinical variables of the 98 coronary artery disease patients according to serum leptin levels

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables                             All participants\        Low leptin group\        High leptin group\       *P*-value
                                        (n = 98)                 (n = 49)                 (n = 49)                 
  ------------------------------------- ------------------------ ------------------------ ------------------------ ---------------------------------------------------
  Age (years)                           65.65 ± 8.71             63.67 ± 8.39             67.63 ± 8.66             0.024[a](#tfn2-tcrm-14-1855){ref-type="table-fn"}

  Height (cm)                           161.84 ± 7.54            163.51 ± 7.27            160.16 ± 7.50            0.027[a](#tfn2-tcrm-14-1855){ref-type="table-fn"}

  Body weight (kg)                      67.77 ± 11.05            67.96 ± 10.58            67.58 ± 11.60            0.867

  Body mass index (kg/m^2^)             25.78 ± 3.11             25.28 ± 2.51             26.28 ± 3.58             0.115

  SBP (mmHg)                            131.90 ± 18.10           130.65 ± 17.46           133.14 ± 18.81           0.499

  DBP (mmHg)                            71.94 ± 9.46             71.16 ± 10.05            72.71 ± 8.87             0.420

  Total cholesterol (mg/dL)             164.95 ± 33.03           164.98 ± 35.37           164.92 ± 30.88           0.993

  Triglycerides (mg/dL)                 116.00 (89.75--165.00)   109.00 (88.50--152.00)   121.00 (91.50--174.00)   0.670

  HDL-C (mg/dL)                         44.98 ± 12.46            44.86 ± 11.55            45.10 ± 13.43            0.923

  LDL-C (mg/dL)                         96.36 ± 25.90            97.86 ± 27.06            94.86 ± 24.87            0.569

  Fasting glucose (mg/dL)               107.50 (95.00--134.00)   105.00 (98.50--130.00)   108.00 (93.50--164.00)   0.898

  Blood urea nitrogen (mg/dL)           16.70 ± 5.56             17.12 ± 5.43             16.29 ± 5.71             0.459

  Creatinine (mg/dL)                    1.10 (0.90--1.30)        1.10 (0.90--1.30)        1.00 (0.90--1.25)        0.317

  Glomerular filtration rate (mL/min)   68.87 ± 19.09            68.71 ± 19.77            69.02 ± 18.59            0.936

  Leptin (ng/mL)                        6.03 (3.37--13.69)       3.40 (1.82--4.31)        13.60 (8.46--28.81)      ,0.001a

  C-reactive protein (mg/dL)            0.20 (0.14--0.26)        0.18 (0.14--0.23)        0.21 (0.16--0.37)        0.015[a](#tfn2-tcrm-14-1855){ref-type="table-fn"}

  Female (%)                            21 (21.4)                7 (14.3)                 14 (28.6)                0.085

  Diabetes (%)                          47 (48.0)                25 (51.0)                22 (44.9)                0.544

  Hypertension (%)                      76 (77.6)                37 (75.5)                39 (79.6)                0.628

  ACE inhibitor use                     29 (29.6)                16 (32.7)                13 (26.5)                0.507

  ARB use                               37 (37.8)                16 (32.7)                21 (42.9)                0.297

  β-blocker use                         58 (59.2)                28 (57.1)                30 (61.2)                0.681

  CCB use                               33 (33.7)                14 (28.6)                19 (38.8)                0.285

  Statin use                            71 (72.4)                34 (69.4)                37 (75.5)                0.498

  Fibrate use                           14 (14.3)                4 (8.2)                  10 (20.4)                0.083
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** Values for continuous variables given as mean ± SD and compared by Student's *t*-test; variables not normally distributed given as medians and interquartile range and compared by Mann--Whitney *U* test; values are presented as number (%), and analysis was performed using the chi-squared test.

*P*\<0.05.

**Abbreviations:** ACE, angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; CCB, calcium-channel blocker; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure.

###### 

Clinical variables of the 98 coronary artery disease patients with or without cardiovascular event

  Variables                             Participants without cardiovascular events (n = 55)   Participants with cardiovascular events (n = 43)   *P*-value
  ------------------------------------- ----------------------------------------------------- -------------------------------------------------- ---------------------------------------------------
  Age (years)                           66.00 ± 8.60                                          65.21 ± 8.94                                       0.658
  Height (cm)                           162.13 ± 7.67                                         161.47 ± 7.45                                      0.668
  Body weight (kg)                      67.40 ± 11.16                                         68.25 ± 11.02                                      0.709
  Body mass index (kg/m^2^)             25.56 ± 3.27                                          26.07 ± 2.91                                       0.425
  SBP (mmHg)                            128.40 ± 15.49                                        136.37 ± 20.28                                     0.030[a](#tfn5-tcrm-14-1855){ref-type="table-fn"}
  DBP (mmHg)                            70.98 ± 10.13                                         73.16 ± 8.49                                       0.260
  Total cholesterol (mg/dL)             158.71 ± 27.81                                        172.93 ± 37.53                                     0.034[a](#tfn5-tcrm-14-1855){ref-type="table-fn"}
  Triglycerides (mg/dL)                 108.00 (89.00--151.00)                                129.00 (91.00--195.00)                             0.184
  HDL-C (mg/dL)                         44.27 ± 11.19                                         45.88 ± 14.01                                      0.528
  LDL-C (mg/dL)                         93.05 ± 23.94                                         100.58 ± 27.92                                     0.154
  Fasting glucose (mg/dL)               106.00 (95.00--132.00)                                108.00 (95.00--157.00)                             0.564
  Blood urea nitrogen (mg/dL)           16.75 ± 5.68                                          16.65 ± 5.47                                       0.934
  Creatinine (mg/dL)                    1.10 (0.90--1.30)                                     1.00 (0.90--1.40)                                  0.746
  Glomerular filtration rate (mL/min)   68.29 ± 17.44                                         69.61 ± 21.20                                      0.736
  Leptin (ng/mL)                        4.59 (2.79--8.51)                                     9.91 (4.32--34.49)                                 0.001[a](#tfn5-tcrm-14-1855){ref-type="table-fn"}
  C-reactive protein (mg/dL)            0.18 (0.14--0.24)                                     0.21 (0.17--0.37)                                  0.018[a](#tfn5-tcrm-14-1855){ref-type="table-fn"}
  Female (%)                            11 (20.0)                                             10 (23.3)                                          0.697
  Diabetes (%)                          24 (43.6)                                             23 (53.5)                                          0.333
  Hypertension (%)                      39 (70.9)                                             37 (88.6)                                          0.075
  ACE inhibitor use                     19 (34.5)                                             10 (23.3)                                          0.224
  ARB use                               17 (30.9)                                             20 (46.5)                                          0.114
  β-blocker use                         32 (58.2)                                             26 (60.5)                                          0.819
  CCB use                               15 (27.3)                                             18 (41.9)                                          0.129
  Statin use                            42 (76.4)                                             29 (67.4)                                          0.327
  Fibrate use                           6 (9.1)                                               9 (20.9)                                           0.096

**Notes:** Values for continuous variables given as mean ± SD and compared by Student's *t*-test; variables not normally distributed given as medians and interquartile range and compared by Mann--Whitney *U* test; values are presented as number (%), and analysis was performed using the chi-squared test.

*P* \< 0.05 was considered statistically significant.

**Abbreviations:** ACE, angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; CCB, calcium-channel blocker; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure.

###### 

Cox regression of univariate and multivariate significant predictors of cardiovascular events among the 98 patients with coronary artery disease

                                        Univariate             Multivariate                                                                 
  ------------------------------------- ---------------------- ----------------------------------------------------- ---------------------- -----------------------------------------------------
  Age (years)                           0.995 (0.961--1.030)   0.779                                                 --                     --
  Height (cm)                           0.995 (0.957--1.035)   0.801                                                 --                     --
  Body weight (kg)                      1.006 (0.979--1.034)   0.679                                                 --                     --
  Body mass index (kg/m^2^)             1.035 (0.941--1.139)   0.475                                                 --                     --
  SBP (mmHg)                            1.018 (1.003--1.034)   0.021[a](#tfn7-tcrm-14-1855){ref-type="table-fn"}     --                     --
  DBP (mmHg)                            1.020 (0.988--1.053)   0.222                                                 --                     --
  Total cholesterol (mg/dL)             1.010 (1.001--1.020)   0.035[a](#tfn7-tcrm-14-1855){ref-type="table-fn"}     --                     --
  Triglycerides (mg/dL)                 1.004 (1.001--1.006)   0.006[a](#tfn7-tcrm-14-1855){ref-type="table-fn"}     1.010 (1.001--1.018)   0.022[a](#tfn7-tcrm-14-1855){ref-type="table-fn"}
  HDL-C (mg/dL)                         1.007 (0.983--1.032)   0.563                                                 --                     --
  LDL-C (mg/dL)                         1.008 (0.996--1.021)   0.180                                                 --                     --
  Fasting glucose (mg/dL)               1.002 (0.996--1.007)   0.527                                                 --                     --
  Blood urea nitrogen (mg/dL)           1.006 (0.955--1.060)   0.825                                                 --                     --
  Creatinine (mg/dL)                    1.138 (0.457--2.832)   0.781                                                 --                     --
  Glomerular filtration rate (mL/min)   1.002 (0.985--1.019)   0.822                                                 --                     --
  Leptin (ng/mL)                        1.043 (1.025--1.062)   \<0.001[a](#tfn7-tcrm-14-1855){ref-type="table-fn"}   1.054 (1.026--1.082)   \<0.001[a](#tfn7-tcrm-14-1855){ref-type="table-fn"}
  C-reactive protein (mg/dL)            4.329 (2.027--9.246)   \<0.001[a](#tfn7-tcrm-14-1855){ref-type="table-fn"}   --                     --
  Female (%)                            1.138 (0.560--2.311)   0.721                                                 --                     --
  Diabetes (%)                          1.336 (0.733--2.434)   0.345                                                 --                     --
  Hypertension (%)                      2.052 (0.865--4.868)   0.103                                                 --                     --

**Note:**

*P* \< 0.05 was considered statistically significant.

**Abbreviations:** DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure.
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